Opinion

Video

Batteryless neurostimulator found efficacious at 6-month follow-up

"I think we're all going to be very eager to see what happens to these patients over time," says Colin Goudelocke, MD.

In this video, Colin Goudelocke, MD, discusses the significance of the findings of the study “Treatment of OAB symptoms using Neuspera’s ultra-miniaturized system: 6-month results of the SANS-UUI phase II study,” which was presented at the Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction 2025 Winter Meeting. Goudelocke is a urologist with Ochsner Health Center in Covington, Louisiana.

Transcription:

You mentioned the pSNM system offers "consistent relief." Can you describe the stability of the therapeutic effect over the 6-month study period?

Let's be honest, so 6 months, right? Anytime we talk about overactive bladder, this is a disease that we don't have a cure for, so we always need to think about these patients over their lifetime. These are relatively early data. Obviously, I think we're all going to be very eager to see what happens to these patients over time. How are they doing in a year and as we're implanting this, who will be implanting this in clinical practice? How are these patients going to do over the long term? I'm certainly interested to see the patients that I implanted as part of the clinical trial, how are they doing at a year and beyond? However, I think 6 months is important for me as a practitioner, as a provider, someone who's seeing patients every day, because a lot of the issues that I see in sacral neuromodulation tend to pop up in 6 months. Most of the time when I'm seeing infections at the battery site—luckily, that's not too often—but when we do see infections at the battery site, that's usually going to be well inside of 6 months. Patients who have displeasure with the battery, or patients who have a rechargeable device that when they're starting to get a little frustrated with recharging sometimes, or even those patients, when we we tend to see some lack of efficacy over time, or some decrease in efficacy over time, I think most of those problems, at least in my anecdotal experience, those tend to happen at6 months. So even though this is relatively early in the course of someone who's going to have overactive bladder for the rest of his or her life, I do think there's something that's really important about 6 months, and it's certainly why I think the data are relevant to my practice.

This transcript was AI generated and edited by human editors for clarity.

Related Videos
Man talking with a doctor | Image Credit: © Chinnapong - stock.adobe.com
Colin Goudelocke, MD, answers a question during a Zoom video interview
Prostate cancer cells dividing | Image Credit: © PRB ARTS - stock.adobe.com
Vanita Gaglani, RPT, answers a question during a video interview
© 2025 MJH Life Sciences

All rights reserved.